No end in sight to wave of pharma dealmaking

Deals driven by cheap capital and race to develop new treatments

Clinigen set to lead unlicensed drugs market

UK pharma distributor sees £225m deal boost

Small-cap Week, April 25

Shoe Zone warns on lower average selling prices

Three-way drugs merger battle hots up

Perrigo rejects formal offer from bigger rival Mylan

AstraZeneca forced to defend Celgene deal

Drugmaker accused of trading future growth for short-term gains

RDT malaria test
©Jonathan Torgovnik

Tests get cheaper and more sensitive

Rapid diagnosis could help detect victims who are unwittingly spreading the disease

a baby is given an injection as part of a malaria vaccine trial at a clinic in the Kenya coastal town of Kilifi, November 23, 2010
©Joseph Okanga/Reuters

Scientists target people and mosquitoes

The first malaria vaccine will be a milestone but not a magic bullet

A worker from Haiti's Ministry of Public Health and Population sprays chemicals to exterminate mosquitoes in a neighborhood of Petion Ville in Port-au-Prince on May 21, 2014
©Hector Retamal/Getty

Haiti revives eradication aim

Recent experience and limited funding point to the need for a more targeted approach

infrared tracking of multiple mosquitoes attempting to reach a human volunteer
©Liverpool School of Tropical Medicine/Univers

Fight intensifies against a killer disease

Despite progress, existing treatments and pesticides are losing their effectiveness

Professor James McCarthy with a volunteer for antimalarial drug testing using the Human Challenge Model

Human trials speed up delivery of vaccines

Australian drug trial research on healthy volunteers is attracting international donors

Race against time to kill resistant mosquitoes

Scientists and manufacturers must innovate to avoid a catastrophe in the decades to come

Huge costs have been a call to action

Efforts have reduced prevalence but much more needs to be done

Novartis starts to reap rewards of revamp

Earnings hurt by strong dollar but underlying profits helped by better productivity

Mylan readies its poison pill defences

Group changes its corporate governance as Teva pursues $40bn bid

Roche boosted by US drugs sales

Pharma group shrugs off impact of strong Swiss franc

Deal would cushion Teva from patent loss

Takeover offer thrusts pillar of Israeli economy into spotlight

Teva/Mylan: brand management

Good market for pharma buyers means better market for sellers

Teva offers $40.1bn for US rival Mylan

Cash-and-shares proposal continues consolidation in pharma sector

Japan’s Daiichi closes book on India foray

Drugmaker sells its entire 8.9% stake in Sun Pharma

Bristol-Myers cancer drugs shows promise

Phase-two trial finds tumour shrinkage in 59% of participants


More FT Twitter accounts